HighGravityData
Companies / Biopharma / LLY

Eli Lilly

LLY · Biopharma sector group
Guidance from Eli Lilly’s last 8 earnings releases. Every value links to its sentence in the filing. See something wrong? Tell us.
Current guidance
11 items
Releases tracked
8
Latest release
Aug 5, 2026
Data checked
Aug 5, 2026
On this page:Latest changes·Current guidance·Your sector group·History

What changed in the Aug 5, 2026 release

Each item compared with the same item in the previous release (Apr 30, 2026). Values in quotation marks are the company’s words.

New — first stated in this releaseRaised / Lowered / Narrowed / Widened — changed from the prior releaseRevised — wording changed, direction not determinableChanged — value changed; the comparison couldn’t be parsed to a directionReiterated — restated unchangedNot restated — stated before, absent nowRaised and lowered describe the number, not whether the change is favorable.
ChangeMetricPeriodPreviousNowSource
NewFull-year revenuefor FY2026—“$85.0 billion to $87.0 billion”Filing ↗
RaisedRevenuefor FY2026“$82 to $85 billion”“$85 to $87 billion”Filing ↗
NarrowedEarnings per Sharefor FY2026“$35.50 to $37.00”“$35.50 to $36.50”Filing ↗
NewNon-GAAP EPSfor FY2026—“$35.50 to $36.50”Filing ↗
RaisedPerformance Marginfor FY2026“47.0% to 48.5%”“49.0% to 50.5%”Filing ↗
ReiteratedTax Ratefor FY2026“18% to 19%”“18% to 19%”Filing ↗
Show 2 items not restated in this release
ChangeMetricPeriodPreviousNowSource
Not restatedEarnings per Share (2)(3)(4)for FY2026“$33.50 to $35.00”—Filing ↗
Not restatedPerformance Margin (1)(2)for FY2026“46.0% to 47.5%”—Filing ↗

Current guidance

Guidance for periods that have not yet ended, at its most recent value, grouped by horizon.

Current fiscal year
MetricCurrent valuePeriodMeasureFirst statedTimes statedSource
Full-year revenue“$85.0 billion to $87.0 billion”for FY2026GAAP-tiedAug 5, 20261Filing ↗
Revenue“$85 to $87 billion”for FY2026GAAP-tiedFeb 4, 20263Filing ↗
Revenue“$82.0 billion to $85.0 billion”for FY2026GAAP-tiedApr 30, 20261Filing ↗
Earnings per Share“$35.50 to $36.50”for FY2026GAAP-tiedApr 30, 20262Filing ↗
Earnings per Share (2)(3)(4)“$33.50 to $35.00”for FY2026GAAP-tiedFeb 4, 20261Filing ↗
Non-GAAP EPS“$35.50 to $36.50”for FY2026Company-definedAug 5, 20261Filing ↗
Non-GAAP EPS“$35.50 to $37.00”for FY2026Company-definedFeb 4, 20262Filing ↗
Performance Margin“49.0% to 50.5%”for FY2026Company-definedApr 30, 20262Filing ↗
Performance Margin (1)(2)“46.0% to 47.5%”for FY2026Company-definedFeb 4, 20261Filing ↗
Tax Rate“18% to 19%”for FY2026Company-definedApr 30, 20262Filing ↗
Tax Rate (2)(3)“18% to 19%”for FY2026Company-definedFeb 4, 20261Filing ↗

How one item moved

Revenue, for FY2026 — every statement across the year, each linked to its filing.

Feb 4, 2026
New
“$80 billion to $83 billion”
Filing ↗
Apr 30, 2026
Raised
“$82 to $85 billion”
Filing ↗
Aug 5, 2026
Raised
“$85 to $87 billion”
Filing ↗

How your Biopharma sector group guides

12 companies in Biopharma. What they guide on, and who reported this season.

Most-guided metric families
Revenue
11
Adjusted EPS
6
GAAP EPS
5
Tax rate
5
Buybacks
5
Gross margin
4
Capex
3
Dividends
3
This season’s releases
BioMarin PharmaceuticalAug 6, 202619 changes
Halozyme TherapeuticsAug 6, 20266 changes
Eli LillyAug 5, 20265 changes
AmgenAug 4, 20265 changes
Gilead SciencesAug 4, 202615 changes
ModernaJul 31, 20268 changes
Neurocrine BiosciencesJul 30, 202616 changes
Regeneron PharmaceuticalsJul 30, 202622 changes
Get this for your own peer set — Peer Guidance Briefing, $3,000.

Full history

Every metric, every release, eight quarters — the complete record as one table.

MetricFY2026FY2025FY2024No period
(Gross Margin - OPEX)/Revenue (non-GAAP)——1 statement—
(Gross Margin - OPEX)/Revenue (reported)——1 statement—
Full-year revenue5 statements4 statements2 statements—
Full-year worldwide revenue——2 statements—
Mounjaro revenue——1 statement—
The full record for Eli Lilly and its Biopharma peers, delivered as a Peer Guidance Briefing — PDF and Excel, every value linked to its filing.

Filings

The 8 earnings releases this page is built from.

FiledFiscal periodAccessionGuidance items
Aug 5, 2026FY2026 Q20000059478-26-0000777Open filing ↗
Apr 30, 2026FY2026 Q10000059478-26-0000436Open filing ↗
Feb 4, 2026FY2025 Q40000059478-26-0000085Open filing ↗
Oct 30, 2025FY2025 Q30000059478-25-00025112Open filing ↗
Aug 7, 2025FY2025 Q20000059478-25-00020213Open filing ↗
May 1, 2025FY2025 Q10000059478-25-00012912Open filing ↗
Jan 14, 2025FY2024 Q40000059478-25-0000058Open filing ↗
Oct 30, 2024FY2024 Q30000059478-24-00024212Open filing ↗

Not located in filing

3 values were detected in these releases but could not be matched to an exact sentence in the filing body, so they are not shown as guidance. We surface the count rather than drop it silently.

Show the 3 unmatched spans
SpanWhyFiled
tax rate, non-GAAP basis = approximately 17%span gate: value not verbatim in filingOct 30, 2025
Estimated effective tax rate (non-GAAP) = approximately 17%span gate: value not verbatim in filingOct 30, 2025
Q4 2024 Zepbound revenue = approximately $1.9 billionspan gate: value not verbatim in filingJan 14, 2025
Values in quotation marks are the company’s words; the classification and filing links are HighGravityData’s. HighGravityData does not score or rank companies or give investment advice.
Report an error